More precisely, patient-related variables pertaining to liver cancers and its effects (mostly tumor burden, fibrinogen concentration, platelet count, presence of hypercoagulability at viscoelastic tests, TF+MVs), as well as the clinical scenario (cirrhotic patient with HCC waiting for liver transplantation, invasive procedures) should be taken into consideration to ascertain in which cases the benefits of thromboprophylaxis exceed the risk of anticoagulation. Here, TF is linked to neoplasm.